March 2, 2026 8:30am

Blast radius widens to indexes and sectors in new month with the cell and gene therapy (C&GT) sector earnings are still a’comin

Q4/25 & FY25 Earnings: uniQure NV (QURE)

Pre-open Signals: 5 Negative Indications; if you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

 

 

Stock futures tumbled on Monday after the U.S. and Israel attacked Iran over the weekend, causing oil prices to surge and adding an unstable Middle East to a list of growing worries for equity investors.

Friday’s RMi Closing Bell: Econs crush indexes and share pricings …https://www.regmedinvestors.com/articles/14332   

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Monday: The pre-open Dow futures are DOWN -1.01% or (-497 points), the S&P futures are DOWN -1.09% or (-74 points) and the Nasdaq futures are DOWN -1.45% or (-362 points)

  • U.S. stock futures
  • European markets
  • Asia Pacific markets

Economic Data: S&P final U.S. manufacturing PMI - Feb., ISM manufacturing - Feb. and Auto sales

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed DOWN -521.28 points or -1.05%, the S&P closed DOWN -29.98 points or -0.43% while the Nasdaq closed DOWN -210.1711 points or -0.92%
  • Thursday: The Dow closed UP +17.05 points or +0.03%, the S&P closed DOWN -37.27 points or -0.54% while the Nasdaq closed DOWN -273.694 points or -1.18%
  • Wednesday: The Dow closed UP +307.65 points or +0.63%, the S&P closed UP +56.06 points or +0.81% while the Nasdaq closed UP +288.396 points or +1.26%
  • Tuesday: The Dow closed UP +370.44 points or +0.76%, the S&P closed UP +52.32 points or +0.77% while the Nasdaq closed UP +236.409 points or +1.05%
  • Monday: The Dow closed DOWN -821.91 points or -1.66%, the S&P closed DOWN -71.76 points or -1.04% while the Nasdaq closed DOWN -258.796 points or -1.13%

 

  • Last week: The Dow finished down 1.3% for the week, the NASDAQ declined 0.9%, and the S&P 500 slipped 0.4%. 
  • The previous week: The S&P 500 was up +1.1%, the Dow +0.3% and the Nasdaq was up +1.5%.
  • February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 - March

  • February – 1 market holiday, 11 positive and 8 negative closes
  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4:

  • December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

The CBOE Volatility Index (VIX) fear gauge based on option prices used to hedge against losses, jumped to the highest levels of 2026 so far.

  • A risk-off mentality sent most stocks lower with tech and banking shares leading the losses
  • Presume a shorter-term impact, but can’t rule out a more protracted friction to equities,” said Citi equity strategists in a note to clients about the Middle East conflict. “We also need to bucket this new volatility event alongside a growing list of concerns. Namely, the AI spending boom seems poised to persist, but the productivity promise is quickly facing off against AI-triggered business-model disruption.” <CNBC>

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings coming as sector releases Qs and FY25 …

Vertex (VRTX) closed up +$16.70 after Thursday’s -$2.70 after Wednesday’s -$4.60 after Tuesday’s +$6.42 after Monday’s +$4.1 with a negative -$0.77 or -0.15% pre-open

Capricor Therapeutics (CAPR) closed up +$0.04 after Thursday’s -$0.46 after Wednesday’s +$0.44 with a negative -$1.08 or -3.87% pre-open

CRISPR Therapeutics (CRSP) closed down -$1.60 after Thursday’s +$6.54 after Wednesday’s -$1.57 after Tuesday’s +$2.79 after Monday’s +$0.52 with a negative -$3.29 or -5.47% pre-open

BioNTech (BNTX) closed up +$1.43 after Thursday’s -$1.04 after Wednesday’s +$1.05 after Tuesday’s +$0.96 after Monday’s -$0.21 with a negative - $2.93 or -2.66% pre-open

Moderna (MRNA +$1.86 after Thursday’s +$0.34 after Wednesday’s +$0.85 with a negative -$1.37 or -2.56% pre-open

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

“Stock futures tumbled and oil prices surged early Monday as the conflict in the Middle East shook up global markets. S&P 500 futures also dropped 1.1%, and contracts tied to the tech-heavy Nasdaq 100 plunged 1.4%. Oil was rallying as traders worried that the war in Iran would disrupt traffic through the Strait of Hormuz.” <Barron’s>

 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Are the dice … hot, as they say it is a “crap shoot”        

  • Keep that in mind   the latest batch of buying opportunities. If you take advantage, you have to be nimble, cutting losers quickly and not letting small winners turn into losers. <IBD>

 

Investors will look for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday – 3/2 uniQure NV (QURE)
  • Thursday - 3/5 Regenxbio (RNX)
  • Tuesday – 3/10 – BioNTech, SE (BNTX)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

February – last week

  • 2/27 – Friday closed negative with 12 incliners, 26 decliners and 2 flats
  • 2/26 – Thursday closed positive with 24incliners, 14 decliners and 2 flats
  • 2/25 – Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.